TickerFacts.

Longeveron Inc. (LGVN): Cost of Revenue

Annual figures by period end, from SEC filings.

$396.0K
Year ended 2025-12-31
$359.0K
Trailing 12 months to 2026-06-30
-18.3%
3-year compound annual growth
-36.4%
5-year compound annual growth
$3.80M2020-12-31: $3.80M2021-12-31: $716.0K2022-12-31: $725.0K2023-12-31: $488.0K2024-12-31: $508.0K2025-12-31: $396.0K$396.0K
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$396.0K-22.0%2026-03-17, From 2025-01-01
2024-12-31$508.0K+4.1%2026-03-17, From 2024-01-01
2023-12-31$488.0K-32.7%2025-02-28, From 2023-01-01
2022-12-31$725.0K+1.3%2024-02-27, From 2022-01-01
2021-12-31$716.0K-81.2%2023-03-14, From 2021-01-01
2020-12-31$3.80Mn/a2022-03-11, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Longeveron Inc. (LGVN)2025-12-31$396.0K-22.0%
China SXT Pharmaceuticals, Inc. (SXTC)2026-03-31$889.4K-35.2%
IGC Pharma, Inc. (IGC)2025-03-31$652.0K+6.5%
Bespoke Extracts, Inc. (BSPK)2024-12-31$664.5K+50.2%
Cannapharmarx, Inc. (CPMD)2025-12-31$3.45M-8.2%
Dare Bioscience, Inc. (DARE)2025-12-31$295.8Kn/a
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$781.7K+103.2%
NRX Pharmaceuticals, Inc. (NRXP)2025-12-31$505.0Kn/a
Onconetix, Inc. (ONCO)2025-12-31$182.5K-87.6%

Compare LGVN, SXTC, IGC, BSPK side by side · Screen every company in Pharmaceutical Preparations ↗